Global Clopidogrel Market Research Report 2020 (Includes Business Impact of COVID-19)

                                          
Clopidogrel, sold as the brandname Plavix among others, is an antiplatelet medication that is used to reduce the risk of heart disease and stroke in those at high risk. It is also used together with aspirin in heart attacks and following the placement of a coronary artery stent. It is taken by mouth.

Clopidogrel has remained, ever since its first approval in 1997, the antiplatelet therapy of choice among physicians for the treatment of patients with conditions such as acute coronary syndrome or percutaneous coronary intervention. The drug was the first thienopyridine to hit the market, which gave it an excellent head start over a number of drugs for these conditions that are either available in the market or are in clinical trials. As a result, the drug did not face much competition and has taken over the global market, with its array of application constantly expanding.

The substantial and high-level evidence gathered over the years support the use of Clopidogrel for reduction of mortality and morbidity patients with acute coronary syndrome, myocardial infarction, and a number of other indications. As a result, the drug has developed a formidable presence in the global market over the years. Moreover, the drug’s relative ease of use, low rate of incidence of adverse reactions, and good tolerability have made it the de-facto antiplatelet agent for the reduction of atherosclerotic events in patients.

These factors have helped the global Clopidogrel market to tread along an excellent growth path in the past few years and the market is expected to embark upon a healthy growth path in the next few years as well. However, the overall profitability of the market has reduced to a certain extent owing to entry of a number of generic products post the patent expiry of Clopidogrel manufacture in 2013. Nevertheless, the vast pool of patients prescribed Clopidogrel on an annual basis across the globe will allow market players excellent growth prospects in the next few years.

The global Clopidogrel market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.

This report focuses on Clopidogrel volume and value at global level, regional level and company level. From a global perspective, this report represents overall Clopidogrel market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:


 	
Sanofi (France)
 	
Shenzhen Salubris Pharmaceuticals (China)
 	
Mylan
 	
Lepu Medical Technology (China)

Segment by Type

 	
25mg
 	
75 mg
 	
300 mg

Segment by Application

 	
Hospitals
 	
Private Clinics
 	
Retail Pharmacies
 	
Online Pharmacies
 	
Others
 	


 

In Jan 2020, Mylan S.A.S. received marketing authorization valid throughout the European Union for Clopidogrel/Acetylsalicylic acid Mylan which is a medicine used to prevent problems caused by blood clots and hardening of the arteries, such as a heart attack, in adults who are already taking both clopidogrel and acetylsalicylic acid as separate tablets. It can be used in the following groups of patients who have a condition known as acute coronary syndrome:

patients who have unstable angina (a severe type of chest pain) or who have had a heart attack with no ST-segment elevation (an abnormal reading on an electrocardiogram), including those who are having a stent (a short tube) inserted into an artery to prevent it from closing up;
patients being treated for heart attack with ST-segment elevation, when the doctor thinks that they would benefit from thrombolytic treatment (treatment to dissolve blood clots).
Clopidogrel/Acetylsalicylic acid Mylan contains two active substances, clopidogrel and acetylsalicylic acid (also known as aspirin) and is a generic medicine. This means that Clopidogrel/Acetylsalicylic acid Mylan contains the same active substance and works in the same way as a reference medicine already authorised in the EU called DuoPlavin.